Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
Registro de estudiosClinicalTrials.gov
Año 2010
Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in subjects with adult onset active and progressive Psoriatic Arthritis (PsA).
Epistemonikos ID: b527e9373cf1bb949d95e91b927db9db14283bb9
First added on: Feb 15, 2022